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Abstract
Introduction: The WHO clinical guidelines for HIV/AIDS are widely used in resource limited settings to represent the gold
standard of CD4 counts for antiviral therapy initiation. The utility of the WHO-defined stage 1 and 2 clinical factors used in
WHO HIV/AIDS clinical staging in predicting low CD4 cell count has not been established in Uganda. Although the WHO
staging has shown low sensitivity for predicting CD4,200cells/mm
3, it has not been evaluated at for CD4 cut-offs of
,250cells/mm
3 or ,350 cells/mm
3.
Objective: To validate the World Health Organisation HIV/AIDS clinical staging in predicting initiation of antiretroviral
therapy in a low-resource setting and to determine the clinical predictors of low CD4 cell count in Uganda.
Results: Data was collected on 395 participants from the Joint Clinical Research Centre, of whom 242 (61.3%) were classified
as in stages 1 and 2 and 262 (68%) were females. Participants had a mean age of 36.8 years (SD 8.5). We found a significant
inverse correlation between the CD4 lymphocyte count and WHO clinical stages. The sensitivity the WHO clinical staging at
CD4 cell count of 250 cells/mm
3 and 350cells/mm
3 was 53.5% and 49.1% respectively. Angular cheilitis, papular pruritic
eruptions and recurrent upper respiratory tract infections were found to be significant predictors of low CD4 cell count
among participants in WHO stage 1 and 2.
Conclusion: The WHO HIV/AIDS clinical staging guidelines have a low sensitivity and about half of the participants in stages
1 and 2 would be eligible for ART initiation if they had been tested for CD4 count. Angular cheilitis and papular pruritic
eruptions and recurrent upper respiratory tract infections may be used, in addition to the WHO staging, to improve
sensitivity in the interim, as access to CD4 machines increases in Uganda.
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Introduction
There have been significant declines in HIV-related morbidity
and mortality since the advent of anti-retroviral therapy (ART)
[1,2] Initiation of ART is based on CD4 cell count or being
classified as being in World Health Organisation (WHO) HIV/
AIDS clinical stage III or IV [2]. However, although the CD4 cell
counts testing is critical in the determination of eligibility for ART,
many HIV treatment centres in resource limited settings lack CD4
testing facilities. In the absence of CD4 testing in rural primary
health care facilities, WHO HIV/AIDS clinical staging is used to
recommend when to initiate ART [2,3].
Some previous studies have explored the utility of using other
predictors of low CD4 cell count to guide initiation of antiretroviral
therapy. Other clinical factors, such as anaemia and body mass
index have low sensitivities in detecting eligibility for HAART
initiation [4] while other studies have shown that clinical factors
such as anaemia could double sensitivity if used together with the
WHO clinical staging guidelines [5]. Total lymphocyte counts
,1200 cells/microl used with WHO staging showed good
specificity (.99%) [5], and a good correlation between total
lymphocyte count and CD4 cell count in a Ugandan study [6].
In Uganda, although the availability of CD4 testing is
increasing, its access is limited due to cost and a lack of laboratory
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CD4 testing is not available in decentralized health units that
include district hospitals and health centre IV facilitiesthat serve
the largest population of HIV-infected Ugandans.
The WHO clinical staging system for HIV/AIDS was
developed in 1990 and revised in 2007. It uses clinical parameters
to classify subjects into any one of four categories i.e. stage 1 to IV,
progressing from primary HIV infection to advanced HIV/AIDS.
It is these categories that are used to guide decision making for the
management of HIV/AIDS patients where there is limited access
to laboratory services [7]. These clinical guidelines are readily
available, convenient to the patient, cheap and can be applied by
trained clinicians even in the most remote health facilities.
Initially the WHO clinical staging for HIV/AIDS was used in
line with CD4 cut-offs of 200 cells/mm
3 to make decisions on
ART initiation. However, in Uganda the CD4 cut-off for ART
initiation changed from 200 cells/mm
3 to 250 cells/mm
3 or 350
cells/mm
3 for the World health organisation. Previous studies of
the utility of the WHO HIV/AIDS clinical guidelines for
determining ART eligibility, using the cut-off of ,200 cells/
mm
3 have found the sensitivity to be in the range of 51–52% and
the specificity to be in the range 68–88% [5,8,9]. In a Ugandan
study, the sensitivity was 51% and the specificity was 88% [8].
Despite the wide use of the WHO HIV/AIDS clinical
guidelines in Ugandan primary health care facilities, they have
not yet been evaluated in Uganda against the new CD4 cut-offs for
ART eligibility of ,250cells/mm
3 and ,350 cells/mm
3. Evalu-
ation of the WHO HIV/AIDS staging guidelines in comparison to
the newer CD4 cell count cut-offs for ART eligibility is needed to
determine the potential level of misclassification. In addition,
examination of the individual clinical components of the WHO
HIV disease staging is needed because some clinical factors
associated with stage I or II illness may be predictive of more
advanced immune suppression in Uganda. We postulate that if
there are significant clinical factors in stages I and II that are
predictive of low CD4 counts, they could improve identification of
ART-eligible subjects, thereby reducing the missed opportunities
for timely ART initiation. The goal of this study was therefore to
determine the diagnostic properties (sensitivity, specificity, positive
predictive values and negative predictive values) of the WHO
HIV/AIDS clinical staging guidelines at CD4,250cells/mm
3 and
,350cells/mm
3 and to determine the WHO HIV/AIDS Stage I
and II clinical factors (symptoms and signs) that are predictive of
CD4,250cells/mm
3 and CD4,350 cells/mm
3.
Methods
Study area and subjects selection
To address the study objectives, we conducted a multi-centre,
cross-sectional study from January to April 2007 at three JCRC
sites located at Mengo (in Kampala, the capital city of Uganda),
Jinja (85 kilometres from Kampala) and Kasana (45 kilometres
from Kampala). All the three sites offered free HIV/AIDS
treatment and care at the time of study recruitment. The study
sites were selected for convenience. The number of subjects
enrolled from each site was proportional to the number of ARV
treatment naı ¨ve HIV patients seen at each study site in the
previous 3 months. Subjects aged $18, known HIV positive, ART
treatment naı ¨ve, and consented to participate in the study were
consecutively enrolled to participate in the study.
Data Collection Procedures
Clinicians with training in HIV/AIDS clinical staging admin-
istered structured questionnaires to study participants. They
recorded the socio-demographic data (age, sex, marital status
and occupation), and clinical factors used for the WHO HIV/
AIDS staging guidelines. The latter were used these to determine
the patients’ clinical stage [2]. Blood samples for laboratory
analysis at the Joint Clinical Research Centre (JCRC) were
collected after clinical staging. Complete blood count (CBC), total
lymphocyte count and sputum results were used to guide the
diagnosis of neutropenia, leucopenia, anaemia and presence of
pulmonary tuberculosis. The need for a CBC and/or total
lymphocyte count was determined by the attending physician. The
laboratory staff that handled the specimens was blinded to both
the patients’ identities and their HIV/AIDS clinical stage. The
CBC was determined by Coulter AC
*T 5 Diff CP, while the CD4
cell count was assessed using TriTEST CD4 FITC/CD8PE/CD3
PerCP (TRUCOUNT) reagent method. Quality assurance
procedures are routinely conducted to compare the results to that
of external laboratories (the National Health Laboratory Services
in South Africa and to the UK Neqas in the United Kingdom).
Sample size and Statistical Analysis
The minimum sample size of 385 subjects for the study was
determined using the cross sectional studies with 4Za
2P(12P)4W
2
where W is the width of confidence intervals was 1%, Za at 95%
confidence interval=1.96, with an estimate of 50% of subjects that
were expected to be eligible for ART [10].
We determined the diagnostic properties of the WHO clinical
staging compared to CD4,250cells/mm
3 and ,350 cells/mm
3
and calculated 95% confidence intervals for proportions, using
STATA version 10.0 (STATA Corp, College Station, TX, USA).
We estimated the association between CD4,250cells/mm
3 and
,350 cells/mm
3 and stages I and II clinical features using odds
ratios at 95% confidence intervals. Variables with odds ratios and
p#0.2 at bi-variate analysis were included in a multivariate logistic
regression model to determine the adjusted odds ratios for the
association between clinical stages I & II clinical factors and low
CD4 counts.
Ethical considerations
Ethical approval was obtained from the Faculty of Medicine
Research and Ethics Committee of Makerere University, the Joint
Clinical Research Centre, and the Uganda National Council of
Table 1. Distribution of 395 participants at the CD4 cut-offs
of 250cells/mm
3 and 350cells/mm
3 by WHO HIV/AIDS clinical
stages, and sex.
WHO clinical
stage CD4 cell count cut-offs
Total
N( % )
CD4#250
n( % )
CD4.250
n( % )
CD4#350
n( % )
CD.350
n( % )
I 17 (7.5) 49 (29.0 32 (11.4) 34 (29.8) 66(16.7)
II 88 (38.9) 88(52.1) 111(39.5) 65 (57.0) 176(44.6)
III 73(32.3) 23(13.6) 83 (29.5) 13 (11.4) 96(24.3)
IV 48(21.2) 9 (5.3) 55(19.6) 2(1.8) 57(14.4)
Total 226 (100) 169 (100) 281(100) 114(100) 395(100)
Sex
Male 87(38.5) 40(23.7) 104(37.0) 23(20.2) 127(32.2)
Female 139(61.5) 129(76.3) 177 (63.0) 91(79.8) 268(67.8)
Total (%) 226 (100) 169 (100) 281(100) 114(100) 395(100)
doi:10.1371/journal.pone.0019089.t001
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from each subject before enrolment into the study.
Results
Characteristics of the study population
Between January and April 2007 a total of 417 known HIV
patients were screened. Twenty two (5.3%) participants were
excluded from the study due to; age ,18 years (n=1), prior ART
experience (n=2) and inaccessible CD4 results (n=19). A total of
395 participants were enrolled into the study. The subjects were
enrolled from JCRC Mengo (75%), Jinja (14%) and Kasana
(11%). The majority (61%) of the 395 subjects were classified as in
clinical stages 1 and 2. Over two thirds, (68%) of all enrolled
subjects were females. (Table 1). Three hundred and sixty five
(92%) had attained primary level education and 117 (29.6%) were
in the reproductive age group (18–49 years).
The median CD4 cell count of those in WHO HIV/AIDS
clinical stages 1 and 2 was significantly higher than that of
participants in clinical stages 3 and 4. (Figure 1) We found a highly
significant but moderately strong correlation between the CD4
lymphocyte count and WHO clinical stage (spearman correla-
tion=20.498, p,0.01). Female participants had a significantly
higher mean CD4 cell count 307.23 cells/mm
3 (SD=270.93) as
compared to male participants with 216.77 cells/mm
3
(SD=226.08), (p,0.0012), while the mean CD4 counts among
the urban-based population was higher at 301.62 cells/mm
3
(SD=260.57) compared to the rural-based population with CD4
cell count of 206.03 cells/mm
3 (248.12), p,0.0016.
Diagnostic properties of the WHO HIV/AIDS clinical
staging guidelines
The sensitivities of the WHO clinical staging at CD4 cell count
cut-offs of 250 cells/mm
3 and 350 cells/mm
3 were 53.5% and
49.1%, while the specificities were 81.1% and 86.8% at CD4
counts of 250cells/mm
3 and 350 cells/mm
3. The positive
predictive values at CD4 cell count of 250cells/mm
3 and
350cells/mm
3 was 79.1% and 90.2%, and the negative predictive
values were 56.6% and 40.9%, respectively. (Table 2) There were
no significant differences in the sensitivities and specificities of the
WHO HIV/AIDS clinical staging guidelines at the different cut
offs (CD4,250 cells/mm
3 and CD4,350cells/mm
3).
Stage II WHO HIV/AIDS Clinical predictors of low CD4
count
Angular cheilitis and papular pruritic eruptions (Table 3) were
found to be significant predictors of CD4 cell count ,250cells/
mm
3 while angular cheilitis and recurrent upper respiratory tract
infections (Table 4) were found to be significant predictors of
CD4,350cells/mm
3 in multivariate analysis. Angular cheilitis was
defined as having splits or cracks on lips at the corner of the mouth
with possible de-pigmentation, or having been successfully treated
with an antifungal for angular cheilitis. Papular pruritic eruptions
Figure 1. The Box plots showing the median and Inter quartile ranges CD4 cell counts of 395 participants by the WHO HIV/AIDS
clinical stages I–IV.
doi:10.1371/journal.pone.0019089.g001
Table 2. Diagnostic characteristics of the WHO HIV/AIDS
clinical staging guidelines at the CD4 cell count of less than
250 cells/mm
3 and 350 cells/mm
3 among 395 participants in
JCRC Mengo, Kakira and Kasana health centres, Uganda.
Diagnostic
characteristics
Values at
CD4,250cells/mm
3
(95% CI)
Values at
CD4,350cells/mm
3
(95% CI)
Sensitivity 53.5% (47–60) 49.1% (43–55)
Specificity 81.1% (75–87) 86.8% (81–93)
Positive Predictive Value 79.1% (73–86) 90.2% (85–95)
Negative Predictive Value 56.6% (50–63) 40.9% (35–47)
False Positive 18.9% (13–25) 13.2% (07–19)
False Negative 46.5% (40–53) 50.9% (45–57)
doi:10.1371/journal.pone.0019089.t002
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inflammatory skin pigmentation; Recurrent upper respiratory
tract infections were defined as current episode of upper
respiratory tract infection with at least one episode in the past 6
months [11].
The effect of the clinical predictors of low CD4 cell count
on sensitivity of the WHO HIV/AIDS clinical staging
guidelines
To assess the effect of the use of angular cheilitis and papular
pruritic eruption on the sensitivity, specificity and false negative rate
to predict CD4,250cells/mm
3 among patients in Stage I and II, a
variable ‘‘clinical factorpresent’’ was generatedif any of the patients
inStageIIdisease had oneorbothclinicalfactorsofangularcheilitis
and pruritic eruption present. Forty-four subjects out of the 63
subjects (70%) that had either angular cheilitis or pruritic eruption
had a CD4 cell count of ,250cells/mm
3. Thus 44 subjects would
have been correctly considered eligible for ART if any of the two
clinical features had been used, while only 19 of the 63 subjects
would have been started on ART earlier than the required time if
they were considered. The identification of 44 eligible patients using
the supplemental clinical symptoms of angular cheilitis and papular
pruritic eruption would have improved the sensitivity of the clinical
staging from 53.5% to 73.0% and subsequently reduced the false
negative rate from 46.5% to 27%.
To assess the effect of the use of angular cheilitis and recurrent
upper respiratory tract infections on the sensitivity, specificity and
false negative rate to predict CD4,350cells/mm
3 among patients
in Stage I and II, a variable ‘‘clinical factor present’’ was generated
if any of the patients in Stage II disease had one or both clinical
factors of angular cheilitis and recurrent upper respiratory tract
infection present.
Table 3. Association between CD4 cell count ,250cells/mm
3 and the clinical features of the WHO HIV/AIDS clinical Stages I and II
for the 242 participants in stages 1 and 2.
Clinical features
CD4,250 cells/mm
3
N( % )
CD4$250 cells/mm
3
N( % )
Unadjusted
OR
(95% CI) P value
Adjusted
OR
[95% CI] P value
WHO Stage I
Asymptomatic
Yes 17 (25.4) 50 (74.6) 0.34 (0.17-0.64) , 0.001 0.66(0.32-1.37) 0.27
No 88 (50.3) 87 (49.7) 1 1
PGL
Yes 2 6 0.42(0.08-2.16) 0.29
No 103 131 1
WHO Stage II
Recurrent URTI
Yes 41(58.6) 29 (41.4) 2.38(1.34-4.26) 0.0024 1.6(0.84-3.08) 0.15
No 64(37.2) 108 (62.8) 1 1
Moderate weight loss
Yes 49(47.6) 54 (52.4) 1.34 (0.80-2.25) 0.259
No 56 (40.3) 83(59.7) 1
Herpes zoster
Yes 22(43.1) 29 (56.9) 0.98(0.52-1.84) 0.97
No 83 (43.5) 108 (56.5) 1
Angular cheilitis
Yes 20(83.3) 4(16.7) 7.8(2.47-24.75) ,0.000 4.4(1.37-14.1) 0.01
No 85(39.0) 133(61.0) 1 1
Recurrent oral ulcerations
Yes 21(75.0) 7(25.0) 4.64(1.84-11.71) ,0.000 2.4 (0.88-6.28) 0.09
No 84(39.3) 130(60.7) 1
Pruritic eruption
Yes 31(64.6) 17(35.4) 2.95(1.50-5.81) 0.001 2.1(1.02-4.34) 0.04
No 74 (38.1) 120(61.9) 1 1
Seborrhoic dermatitis
Yes 6(60.0) 4(40.0) 2.02 (0.55-7.38) 0.280
No 99 (42.7) 133(57.3) 1
Fungal nail infections
Yes 0(0) 1(100.0) 0.00 0.3813
No 105 (43.6) 136 (56.4) 1
doi:10.1371/journal.pone.0019089.t003
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cheilitis or upper respiratory tract infections on both were found to
have CD4 counts ,350cells/mm
3 and therefore would have been
eligible for ART initiation, while only 18 of the 81 subjects would
have been treated earlier than the required time if it they were
considered. The identification of63 eligible subjects using only
angular cheilitis and recurrent upper respiratory tract infections
would have improved the sensitivity of the clinical staging from
49.1% to 71.5% and subsequently reduced the false negative rate
from 50.9% to 28.5%.
Discussion
Although the WHO HIV/AIDS clinical staging plays a critical
role in guiding primary health workers in initiating antiretroviral
therapy [3,12,13], some studies have reported diagnostic limita-
tions of its use [8,14,15]. Our study findings show a sensitivity of
53.5% and 49.1% for identifying CD4 counts of less than
250cells/mm
3 and 350cells/mm
3, respectively. Our findings
replicate the low sensitivities that have been previously found in
studies of the WHO staging guidelines conducted in Africa
[8,14,15]. The use of cotrimoxazole prophylaxis to prevent some
opportunistic infections may have contributed to the high false
negative rate, despite the low CD4 counts. The low sensitivities
that were found show that about half of the participants would
have missed ART initiation if the WHO clinical staging guidelines
alone were used, which suggests significant diagnostic challenges to
the WHO/HIV AIDS clinical staging guidelines which if used
alone may impact morbidity and mortality [16,17].
We found that the specificity of the WHO HIV/AIDS clinical
staging guidelines were at 81.1% and 86.8% at CD4 counts of
250cells/mm
3 and 350cells/mm
3 respectively, which was also
Table 4. Association between CD4 ,350cells/mm
3 and the Clinical Features of the WHO HIV/AIDS clinical stages I & II among the
242 participants in Stages 1 and 2.
Clinical features
CD4,350
cells/mm
3
N( % )
CD4$350
cells/mm
3
N( % )
Unadjusted
OR
(95% CI) P value
Adjusted
OR
(95% CI) P value
WHO Stage I
Asymptomatic
Yes 31(46.3) 36(57.3) 0.48(0.27-0.86) 0.012 1.05(0.53-2.06) 0.89
No 112 (64.0) 63(36.0) 1 1
PGL
Yes 4 4 0.68(0.17-2.81) 0.60
No 139 95 1
WHO Stage II
Recurrent bacterial URTI
Yes 53(75.7) 17(24.3) 2.84(1.49-5.38) ,0.000 2.48(1.23-5.0) 0.01
No 90(52.3) 82(47.7) 1 1
Moderate weight loss
Yes 65(63.1) 38(36.9) 1.33(0.79-2.26) 0.28
No 78(56.1) 61(43.9) 1
Herpes zoster
Yes 29 (56.9) 22 (43.1) 0.89 (0.48-1.67) 0.72
No 114(59.7) 77 (40.3) 1
Angular cheilitis
Yes 22 (91.7) 2 (8.3) 8.82(1.94-39.99) 0.0006 5.82(1.27-26.8) 0.02
No 121(55.5) 97(44.5) 1 1
Recurrent oral ulcerations
Yes 23 (82.1) 5(17.9) 3.60(1.29-10.0) 0.0085 2.08(0.69-6.22) 0.19
No 120 (56.1) 94(42.9) 1 1
Pruritic eruption
Yes 35(72.9) 13 (27.1) 2.14(1.06-4.33) 0.03 1.56(0.72-3.39) 0.26
No 108 (55.7) 86 (44.3) 1 1
Seborrhoic dermatitis
Yes 8 (80.0) 2(20.0) 2.87 (0.59- 13.9) 0.17 3.83(076-19.3) 0.10
No 135(58.2) 97 (41.8) 1 1
Fungal nail infections
Yes 1 (83.3) 0 (16.7) infinite 0.41
No 142 (70.9) 99 (29.1)
doi:10.1371/journal.pone.0019089.t004
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[8,9,14]. Our results showed positive predictive values at
CD4,250cells/mm
3 and at CD4,350cells/mm
3 of 79.1% and
at 90.2%, respectively; and negative predictive values of 56.6%
and 40.9% respectively.
The finding that females had a higher mean CD4 cell count
than the males is similar to previous findings that demonstrated
that women in stage 1 were less likely to have a lower CD4 cell
count compared to the men [18]. This may be due to the better
health seeking behaviour among women.
The urban based population in this study may have had a
higher mean CD4 cell count compared to the rural population
because of better access to the HIV counselling and testing services
leading to earlier HIV diagnosis.
In our study, we found that angular cheilitis and papular
pruritic eruptions were significant predictors of CD4 cell count
,250cells/mm
3 while angular cheilitis and recurrent upper
respiratory tract infections predicted a CD4 cell count ,350
cells/mm
3. These results are in agreement with a Tanzanian study
that found that HIV associated mucocutaeous manifestations may
improve the sensitivity of the WHO staging guidelines [19]. The
use of three clinical features, of angular cheilitis, papular pruritic
eruption and upper respiratory tract infections might greatly
improve the sensitivity of the WHO HIV/AIDS guidelines in
identifying patients with WHO clinical stages 1 and 2 that are
eligible to start treatment. This is the first study to demonstrate the
utility of the angular cheilitis, papular pruritic eruptions and upper
respiratory tract infections in identifying HIV patients with low
CD4 cell count which would improve on the sensitivity of the
clinical staging guidelines.
While the WHO HIV/AIDS clinical guidelines are an
affordable method to determine ART eligibility, routine or low
cost CD4 T-cell count, as compared with WHO HIV/AIDS
clinical staging in a resource limited setting is very cost-effective for
sub Saharan Africa [20].
However, the availability of the tests and the laboratory
personnel is still limited in Uganda. Therefore, determining other
clinical factors that are predictive of low CD4 cell count in clinical
stages I and II, will be very useful in improving the identification of
subjects eligible for ART initiation until low cost CD4 cell count
testing is widely available in Uganda. We recommend that similar
studies with larger sample sizes be conducted in other developing
countries to assess the role of clinical predictors, in addition to
WHO staging guidelines in determining equivalents to CD4
counts.
Our study had much strength; there was minimal referral bias
since this was a multi centre study. Random error was minimised
by having an adequate sample size for the common clinical
predictors. The study was limited by a lack of sufficient sample size
to detect the association between rare clinical conditions and CD4
counts below 250cells/mm
3 and 350cells/mm
3. Further studies
are recommended to assess the association between rare clinical
features and CD4 cell counts.
WHO HIV/AIDS clinical stage misclassification was minimised
by use of experienced clinicians trained in the study protocols and
blinding of the clinicians to the CD4 results.
Based on the findings of this study, we recommend increased
access to CD4 cell count testing machines in resource limited
settings. In the interim, more study is needed to confirm the
clinical features that we found to be predictive of low CD4 counts.
If these results are confirmed, then ART initiation among persons
with these clinical features should be started regardless of WHO
HIV/AIDS clinical stage. This will go a long way in identifying
more patients eligible for ART.
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